Michel Haïssaguerre

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Retrieved on: 
Monday, August 2, 2021

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.

Key Points: 
  • The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
  • Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
  • Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
  • An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.

Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability

Retrieved on: 
Wednesday, July 28, 2021

The ECLIPSE-AF Trial launched in September 2020 to study the acute safety of Galaxy's flagship CENTAURI system, which uses Pulsed Electric Field (PEF) technology to treat cardiac arrhythmias.

Key Points: 
  • The ECLIPSE-AF Trial launched in September 2020 to study the acute safety of Galaxy's flagship CENTAURI system, which uses Pulsed Electric Field (PEF) technology to treat cardiac arrhythmias.
  • "From the moment we conceived the CENTAURI System, our mission has been to democratize PEF technology, leaving the choice of the mapping system and catheter to the electrophysiologist.
  • Galaxy Medical ( www.galaxymed.com ) is a privately held medical device company based in San Carlos, CA, that is dedicated to developing therapies to treat patients with cardiac arrhythmias.
  • Formed by ATP, a leader in life sciences venture capital, Galaxy is building a portfolio of technologies to address the needs of cardiac electrophysiologists.

OneProjects, VistaMed and Tyndall Institute Awarded Funding to Improve Treatment of Cardiac Arrhythmias

Retrieved on: 
Wednesday, July 14, 2021

Atrial fibrillation or AFib is an irregular heartbeat or cardiac arrhythmia which can lead to blood clots, stroke, and heart failure.

Key Points: 
  • Atrial fibrillation or AFib is an irregular heartbeat or cardiac arrhythmia which can lead to blood clots, stroke, and heart failure.
  • First procedure success rates for patients with atrial fibrillation undergoing cardiac ablation can be as low as 50% and OneProjects aims to increase this significantly.
  • A consortium of three partners were awarded the grant, led by the medical device company, OneProjects with the Tyndall National Institute and VistaMed / Freudenberg Medical .
  • The resulting platform technology will achieve better patient outcomes treating millions of people worldwide who suffer with cardiac arrhythmias, said Patrick Mulholland, Managing Director at VistaMed.

Global Atrial Fibrillation Epidemiology and Patient Flow - 2021 Market Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021

b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Atrial Fibrillation patients, history of the disease at the population level (Atrial Fibrillation prevalence, Atrial Fibrillation incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Atrial Fibrillation patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Atrial Fibrillation market sizing, assessing market potential, and developing drug forecast models\nIdentify Atrial Fibrillation patients segments through age groups, gender, and disease sub-types\nEvaluate Atrial Fibrillation market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005832/en/\n'

Kardium Announces $115M in New Financing for Innovative Atrial Fibrillation Treatment

Retrieved on: 
Monday, January 25, 2021

Kardium Inc. , developer of the Globe Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round.

Key Points: 
  • Kardium Inc. , developer of the Globe Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round.
  • We are tremendously excited to have Fidelity Management & Research Company join Kardium as a major investor, along with the T. Rowe Price funds, said Kevin Chaplin, CEO of Kardium.
  • Kardium was founded in 2007, with the vision of providing a complete solution for the treatment of the worlds most common heart rhythm disorder, atrial fibrillation.
  • Kardium Inc. ( kardium.com ) is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation: the Globe Mapping and Ablation System.

Radcliffe Cardiology Announces New Educational Hub, Arrhythmia Academy

Retrieved on: 
Wednesday, June 10, 2020

LONDON, June 10, 2020 /PRNewswire/ --An exciting new digital platform - 'Arrhythmia Academy' launches today - dedicated to arrhythmia and electrophysiology specialists.

Key Points: 
  • LONDON, June 10, 2020 /PRNewswire/ --An exciting new digital platform - 'Arrhythmia Academy' launches today - dedicated to arrhythmia and electrophysiology specialists.
  • This new scientific content hub is led by Editor-in-Chief Prof Angelo Auricchio, MD, PhD, (Lugano, Switzerland) and is supported by a stellar, international editorial board.
  • In association with leading Cardiovascular content providerRadcliffe Cardiology, Arrhythmia Academy aims to provide high-quality, peer-to-peer content for clinicians interested in cardiac arrhythmias and clinical cardiac care electrophysiology.
  • Editorial Area: regularly updated with key editorials and opinion pieces on a particular issue, event, or gap in the literature.

Insights into the Atrial Fibrillation Industry in North America to 2027 - Featuring Boston Scientific, Medtronic & AtriCure Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 17, 2020

The "North America Atrial Fibrillation Market to 2027 - Regional Analysis and Forecasts by Treatment Type; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Atrial Fibrillation Market to 2027 - Regional Analysis and Forecasts by Treatment Type; End User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The North America atrial fibrillation market is expected to reach US$ 6,284.87 Mn by 2027 from US$ 2,285.69 Mn in 2019.
  • The atrial fibrillation market is growing primarily due to rising number of patients suffering with cardiovascular diseases, and rising awareness regarding atrial fibrillation.
  • Thus, these factors are leading to the cardiovascular conditions and is leading to the rising demand for the atrial fibrillation treatment.

Kardium® announces successful results from the GLOBAL-AF study

Retrieved on: 
Tuesday, October 8, 2019

today announced that the Globe mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study.

Key Points: 
  • today announced that the Globe mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study.
  • The results of the study were published in the Journal of Cardiovascular Electrophysiology .
  • The study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe system.
  • The Globe system is a tremendous innovation in the treatment of atrial fibrillation said Kevin Chaplin, CEO of Kardium.

Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

Retrieved on: 
Thursday, September 12, 2019

Increasing use of electrophysiology devices in the diagnosis and treatment of cardiovascular diseases such as atrial fibrillation, growing demand for cardiac rhythm management devices for continuous monitoring and increasing use of these devices in out-of-hospital settings are some high impact rendering growth drivers of the market."

Key Points: 
  • Increasing use of electrophysiology devices in the diagnosis and treatment of cardiovascular diseases such as atrial fibrillation, growing demand for cardiac rhythm management devices for continuous monitoring and increasing use of these devices in out-of-hospital settings are some high impact rendering growth drivers of the market."
  • Electrophysiology devices are cardiology specialty devices used mainly in the diagnosis and treatment of cardiac arrhythmias and therefore, the growing prevalence of cardiovascular diseases is expected to serve this market as a driver.
  • The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

Retrieved on: 
Tuesday, September 3, 2019

SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010.

Key Points: 
  • SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010.
  • "This large European registry provides important data on the safety, efficacy and use of Brinavess in a real-world clinical setting.
  • Guidelines for the management of atrial fibrillation, The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
  • Correvio and the Correvio Logo are the proprietary trademarks of Correvio Pharma Corp.
    Aggrastat and Brinavess are trademarks owned by Correvio and its affiliates worldwide.